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Abstract: Migraine is a common and painful neurological disorder, with genetic and environmental compo-
nents. Several conditions have been shown to be comorbid with migraine, notably a cardiac malformation af-
fecting the interatrial septum and leading to patent foramen ovale (PFO). Mutations in the development regu-
latory gene GATA-4, located on human chromosome 8p23.1-p22, have been found to be responsible for some 
cases of congenital heart defects including PFO. To determine whether the GATA-4 gene is involved in mi-
graine, the present study performed an association analysis of a common GATA-4 variant that results in a 
change of amino acid (S377G), in a large case/control population (275 unrelated Caucasian migraineurs ver-
sus 275 control individuals). The results showed that there was no significant association for this polymor-
phism between migraine and controls ( = 0.84, P = 0.66). Thus it appears that the GATA-4 (S377G) muta-
tion does not play a significant role in common migraine susceptibility. 
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INTRODUCTION 
 Migraine is a common and debilitating neurological dis-
ease that affects a significant proportion of the population, 
usually affecting 10%-12% of the Western population [1]. 
Characteristic manifestations of migraine include head pain, 
nausea, vomiting, photophobia and often severe neurological 
disturbances [2]. The most common forms of this disorder 
have been classified as migraine with aura (MA) and mi-
graine without aura (MO) [2]. One of the most important 
aspects of the pathophysiology of migraine is the inherited 
nature of the disorder, with twin studies showing the impor-
tance of both genetic and environmental factors [3]. Mi-
graine is now usually viewed as a polygenic multifactorial 
disease, with both environmental and genetic causative fac-
tors, and with multiple possibly interacting genes [4]. The 
age of onset for this disorder also varies, but in females it has 
been found that it is usually at puberty or shortly after, being 
less frequent in middle life and developing three times as 
often in woman as in men [5]. 
 Several disorders have been shown to be comorbid with 
migraine, including epilepsy, asthma, depression, stroke and 
some congenital heart defects [6]. The cardiovascular asso-
ciation between migraine and ischaemic stroke is not coinci-
dental and it could be due to a common genetic component 
and to the presence of different mutations in the same gene 
[7]. One heart disorder that has been associated with  
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migraine is the cardiac malformation, patent foramen ovale 
(PFO) [6]. 
 Patent foramen ovale results from an incomplete anat-
omic fusion of the atrial septum primum and secundum, 
which normally takes place shortly after birth [8]. This con-
dition leads to a persistent connection between the right and 
left atrium of the heart, by which right-to-left shunt may re-
sult
 
[8]. Large shunts more often than small shunts are asso-
ciated with migraine with aura [9, 10]. PFO is believed to 
play a role in cryptogenic stroke via presumed paradoxical 
embolism [11]. The right to left shunt brought about by PFO 
could enhance migraine by affecting systemic levels of brain 
platelet neuromediators, like 5-hydroxytriptamine (5-HT), 
which is normally, inactivated by the pulmonary filter, thus 
triggering a migraine attack [12, 13].  
 Consequently, the increased risk of stroke in patients 
with MA could be explained by an increased propensity to 
paradoxical embolism [8]. The prevalence of PFO in the 
healthy population is approximately 20%-25%. A high 
prevalence of right to left shunt has been observed in patients 
with MA compared to healthy control subjects with a 41%-
48% PFO prevalence in migraine with aura patients [11]. 
 Migraine has been shown to be an independent risk factor 
for subsequent coronary heart disease events among women 
in the Women’s Health Study (WHS) and in men in the Phy-
sician’s Health Study (PHS) [11]. Recent evidence has 
shown that migraineurs who experience an aura are twice as 
likely to have a PFO compared to the general population 
[14]. Association between PFO and migraine has been found 
to be stronger in patients with MA than in those without aura 
[15]. Recent reports have emphasised an association between 
PFO, MA and stroke with 25 patients (PFO was considered 
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to play a causal role in stroke) among 74 consecutive pa-
tients with cryptogenic stroke found to have a 52% preva-
lence of MA [12]. The incidence of PFO in patients with 
migraine is about 50% if migraine is accompanied by visual 
aura, versus 20% in the general population [16]. 
 Mutations in developmental regulatory genes have been 
found to be responsible for some cases of congenital heart 
defects [17]. GATA-4 is one such regulatory gene. It is part 
of the GATA family of zinc finger transcription factors [18], 
which play important roles in transducing nuclear events that 
modulate cell lineage differentiation during development and 
hypertrophy of adult cardiac myocytes [18].  
 To investigate the potential role of GATA-4 gene in mi-
graine an association study of the S377G polymorphism was 
conducted in a migraine case and age, sex and ethnicity 
matched control population. The S377G polymorphism 
(rs3729856) is located in exon 5 of GATA-4 gene and was 
genotyped using a new silica bead-based technology. It is a 
non-synonymous coding polymorphism with an amino acid 
change (serine to glycine) and unpublished studies (R.H., 
L.G., unpublished data) have shown a reasonably high fre-
quency of the S377G rarer allele in Caucasian populations 
(Australian Caucasians (n=400, 13.9%). 
MATERIALS AND METHODS 
Subjects 
 This research has been approved by the Griffith Univer-
sity Ethics Committee for experimentation on human sub-
jects; all participants of the study gave consent. The associa-
tion population has been matched for sex, age (+/- 5 years), 
and ethnicity. All subjects were of Australian Caucasian ori-
gin, interviewed by clinical neurologists and were diagnosed 
for either migraine without aura (MO) or migraine with aura 
(MA) according to the criteria of the International Headache 
Society [2]. None of the subjects were tested for PFO or 
other heart disorders. The study population comprised 275 
migraineurs and 275 unrelated control individuals, with the 
control group matched for sex, age (+/- 5 years), and ethnic-
ity, to minimize potential bias from population stratification.  
Genotyping 
 In this study we utilized standard polymerase chain reac-
tion (PCR) analysis for the genotyping of the migraine 
case/control population (275 unrelated Caucasian mi-
graineurs versus 275 control individuals), using forward 
primer: 5’ TGT CCC CGG CAA ATG TAG ATA AAG’3 
and reverse primer: 5’ CAG TCG GCC TCC CCA CAA 
ACA GC ’3, resulting in a 318 base pair fragment following 
PCR. The thermocycler conditions were 94˚C for 15 minutes 
followed by 40 cycles at 94˚C for 30 seconds, 56˚C for 30 
seconds, and 72˚C for 30 seconds. PCR was completed with 
an extended incubation of 5 minutes at 72˚C. The genotyping 
was undertaken by means of single nucleotide polymorphism 
(SNP) genotyping, using flow cytometry developed by Gen-
era Biosystems. This is a silica bead-based SNP genotyping 
system that discriminates between alleles on the basis of 
competitive hybridisation between fluorescently labelled 
allele specific probes. In addition to the forward and reverse 
primers a mix containing three reagents specific for the SNP 
detection were used. These reagents consisted of, the Am-
paSand
TM
 beads with a covalently bound oligonucleotides 
which is complementary to the ssDNA, an oligonucleotide 
probe specific for one allele labelled with a yellow or green 
dye and an oligonucleotide probe specific for the alternative 
allele labelled with a red dye. Each reaction was analysed by 
a FACSArray flow cytometer. Genotypes for all samples 
were determined by MPlots© software. 
Sequencing 
 The samples were sequenced using ABI Prism 377 dide-
oxy chain termination reaction. To confirm the results previ-
ously obtained by SNP genotyping, 5% of the population 
was sequenced. The sequences produced were analysed 
through the computer software CHROMAS. 
Statistics 
 Chi-square analysis was used to determine if the allele 
frequency of the S377G polymorphism in the GATA-4 gene 
were associated or not with migraine, and if the allele fre-
quencies were significant ( = 0.05). Chi-square analysis 
was also used to determine if the obtained genotype frequen-
cies were in Hardy-Weinberg equilibrium. 
Ethical approval 
 This research was reviewed and approved by the Griffith 
University Human Research Ethics Committee (ethics proto-
Table 1. Distribution of the S377G Polymorphism in Migraineurs and Controls of Original Sample (MO Migraine without Aura, 
MA Migraine with Aura) 
Genotypes (n %) Alleles (allele frequency %) 
Genotypes AA GA GG total (n) A G total (n) 
Migraine 158 (81%) 34 (18%) 2 (1%) 194 350 (90.2%) 38 (9.8%) 388 
FEMALE 111 (81%) 25 (18.2%) 1 (0.8%) 137 247 (90%) 27 (10%) 274 
MALE 47 (82.4%) 9 (15.8%) 1 (1.8%) 57 103 (90.4%) 11 (9.6%) 114 
MA 93 (80.8%) 21 (18.3%) 1 (0.9%) 115 207 (90%) 23 (10%) 230 
MO 65 (82.3%) 13 (16.5%) 1 (1.2%) 79 143 (90.5%) 15 (9.5%) 158 
CONTROL 169 (84.1%) 29 (14.4%) 3 (1.5%) 201 367 (91.3%) 35 (8.7%) 402 
FEMALE 122 (84.1%) 20 (13.8%) 3 (2.1%) 145 264 (91%) 26 (9%) 290 
MALE 47 (83.9%) 9 (16.1%) 0 (0) 56 103 (92%) 9 (8%) 112 
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col number MSC/05/05/HREC) and all subjects participating 
in the study gave informed consent. 
RESULTS  
 To determine whether the GATA-4 mutation had an im-
portant role in migraine, an association analysis of the 
S377G polymorphism in a large case/control population of 
migraineurs was performed. Genotypes for 194 cases and 
201 controls were determined for the case/control tested 
population (275/275). The genotype data can be observed in 
Table 1 as well as the allele frequency for the migraine and 
control populations. Statistical analysis of the S377G poly-
morphism revealed that there was no significant difference 
( = 0.84, P = 0.66) between the migraine population and 
the controls. Moreover there was no significant difference 
observed in the migraine and control population with regards 
to female and males for this particular association study. 
Furthermore no association was found between migraine 
with aura and controls ( = 0.99, P = 0.61), nor between 
migraine without aura and controls ( = 0.2, P = 0.91). 
Hardy Weinberg equilibrium was investigated for both mi-
graine cases and controls. It was found that allele frequencies 
did not deviate from Hardy Weinberg equilibrium in both the 
case and control groups (P = 0.91; P = 0.19). 
DISCUSSION  
 Six family members of have been identified in verte-
brates to be part of the GATA family and have been subdi-
vided in two groups: GATA-1, GATA-2, and GATA-3, which 
are expressed in the hematopoetic system [19]. GATA-4, 
GATA-5 and GATA-6, which are critical for differentiation 
and cell-specific gene expression in different endoderm and 
mesoderm, derived tissues [19]. The human GATA-4 gene is 
located in chromosome 8p23.1-p22 and contains 6 exons 
[20] and regulates its expression through its zinc finger [21]. 
It is widely expressed in the endoderm, mesoderm, heart, 
gonads, liver, small intestine and pancreas [19]. Functional 
studies have shown a role for the GATA-4 gene in cardiac 
embryogenesis [21] and mutations in this gene have been 
found to be associated with congenital heart defects such as 
atrial septal defect (ASD) and patent foramen ovale (PFO) 
[17].  
 Reamon-Buettner et al. (2005) found six mutations in the 
N-finger of GATA-4 in patients with PFO. This includes a 
homozygous deletion (677delC), that would lead to a 
frameshift mutation affecting critical residues arginine and 
histidine [21].  
 A number of studies have found a strong association be-
tween PFO and cryptogenic stroke, due to an increase of 
right heart pressure therefore predisposing to paradoxical 
embolism [22, 23]. A further association that has been in-
creasingly reported is the one between migraine, particularly 
migraine with aura, and PFO [24]. A number of studies have 
shown an increased prevalence of PFO in young patients that 
present with migraine with aura and cryptogenic stroke [8, 
16]. The severity of this disorder varies according to the size 
of the opening found in the heart of the patient. Family stud-
ies suggest that PFO is potentially associated with migraine 
with aura particularly as a risk factor for stroke in women 
[25, 26].  
 The GATA-4 gene contains a common variation that re-
sults in a S377G polymorphism missense mutation with an 
alternative nucleotide of A/G, changing from the serine 
amino acid to the glycine amino acid. The variant is preva-
lent in a number of dispersed Caucasian populations and the 
allele frequency in Australian Caucasians is 13.9% (R.H. and 
L.G., unpublished data). It thus could conceivably play a role 
as a common contributing allele to a disorder like migraine. 
This study aimed to determine the role of the S377G poly-
morphism in the GATA-4 gene in migraine and if there is a 
significant association between patients with migraine and 
this mutation. Genotypes were determined for the S377G 
polymorphism but results showed no association with mi-
graine in the case/control groups studied. Moreover there 
was no significant association found between migraine with 
aura and the control population and no significant difference 
was observed between females with migraine versus control 
females for the migraine population.  
 Several studies have reported a higher prevalence of mi-
graine in patients suffering from congenital heart disease 
[24, 26, 27]. Recently, Hirth and collaborators have studied 
the prevalence between congenital heart disease sufferers 
with migraine [28]. They reported an increased prevalence of 
migraine with aura in congenital heart disease more specifi-
cally in PFO patients (89% of these patients suffer from mi-
graine) [28]. 
 In addition, Tatdelide et al. has studied the prevalence of 
PFO in migraine sufferers [29]. They have found percent-
ages of PFO in migraine patients with aura, without aura and 
Table 2. Chi-Squared (2) Analysis of all Migraine Groups Against Controls for the S377G Polymorphism 
 Genotypes  Alleles  
  P-value  P-value 
Migraine vs Control 0.84 0.66 0.28 0.6 
Subtypes  P-value  P-value 
MA vs Control 0.99 0.61 0.29 0.59 
MO vs Control 0.2 0.91 0.09 0.77 
Mig Female vs Control Fe-
male 
1.85 0.4 0.13 0.72 
Mig Male vs Control Male 0.99 0.61 0.18 0.67 
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the control group were 66.7%, 47.4% and 22.2%, respec-
tively, results suggesting an association between PFO and 
migraine, especially with aura [29]. 
CONCLUSIONS 
 Numerous studies have shown that mutations in the 
GATA-4 gene have a significative role in cardiogenesis and 
are associated with congenital heart defects, like PFO. A 
previous mutation, homozygous deletion 677del C, has been 
found on the N-terminal zinc finger of GATA-4 gene, and 
previously reported in PFO patients [28].  
 Our study has reported a lack of association of the S377G 
polymorphism in the studied migraine population, which 
does not support a correlation between this particular gene 
variant and migraine. It appears that the GATA-4 (S377G) 
mutation does not play a significant role in common mi-
graine susceptibility. However other variants in this gene 
may still play a role in migraine susceptibility. Further stud-
ies investigating other GATA-4 variants in families and 
case/control populations are warranted to more clearly de-
termine whether this gene plays a role in migraine. Further-
more an association study investigating individuals that pre-
sent with both PFO and migraine, particularly migraine with 
aura, would be very interesting and to this end we are cur-
rently collecting subjects with this pertinent information. 
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